Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 18/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 18/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2816064 | 0.82 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL18223770 | 0.81 | CLK4 (0.54) | CLK4 | |
| SCHEMBL1319504 | 0.79 | HCRTR1 (0.53) | HCRTR1HCRTR2 | |
| SCHEMBL17858157 | 0.78 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL3347417 | 0.77 | AR (0.48) | HCRTR1HCRTR2 | |
| SCHEMBL30117156 | 0.77 | HCRTR1 (0.53) | HCRTR1HCRTR2 | |
| SCHEMBL22268674 | 0.77 | HCRTR1 (0.56) | HCRTR1HCRTR2 | |
| SCHEMBL2954326 | 0.76 | HCRTR1 (0.55) | HCRTR1HCRTR2 | |
| SCHEMBL26122716 | 0.76 | HCRTR2 (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL29463458 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101910172-A | N-heterocyclic imidazo [1,2-a ] pyridine-2-carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI AVENTIS | 2010-12-08 | — | — | CN | claimed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2022120355-A1 | TEAD DEGRADERS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2011002407-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| CN-101910172-A | N-heterocyclic imidazo [1,2-a ] pyridine-2-carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI AVENTIS | 2010-12-08 | — | — | CN | disclosed |
| US-20060241151-A1 | Pyrid-2-one derivatives and methods of use | AMGEN, INC. (US) | 2006-10-26 | — | — | US | disclosed |
| EP-1575947-A1 | 2-OXOPYRIDIN-3-YL THIA(DI)AZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | Amgen Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1373264-B1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-6821972-B2 | ANTISCARRING AGENTS; WOUND HEALING AGENTS; ENZYME INHIBITORS | PFIZER INC. | 2004-11-23 | — | — | US | disclosed |
| US-20040147561-A1 | Pyrid-2-one derivatives and methods of use | SYNGENTA CROP PROTECTION AG (CH) | 2004-07-29 | — | — | US | disclosed |
| WO-2004060890-A1 | 2-OXOPYRIDIN-3-YL THIA (DI) AZOLE DERIVATES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | AMGEN INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| EP-1373264-A1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PFIZER INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002079200-A1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
| EP-0051371-B1 | IMIDAZOLYLPYRIDINE THERAPEUTIC AGENTS | PFIZER INC. (US) | 1984-08-29 | — | — | EP | disclosed |
| EP-0051371-A2 | Imidazolylpyridine therapeutic agents | PFIZER INC. (US) | 1982-05-12 | — | — | EP | disclosed |
| US-4302464-A | ANTIULCER AGENTS, ANTI-H2-HISTAMINES | PFIZER INC. (US) | 1981-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147561-A1 | Pyrid-2-one derivatives and methods of use | PLPBP, PNPO, PDXK | HCRTR1 3907/4885HCRTR2 3745/4885EGLN2 1121/4885 |
| US-20060241151-A1 | Pyrid-2-one derivatives and methods of use | PLPBP, PNPO, PDXK | HCRTR1 3870/4885HCRTR2 3725/4885EGLN2 1138/4885 |
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PAH, CYP2F1, CYP7A1 | HCRTR1 469/4885HCRTR2 473/4885EGLN2 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.